荣昌生物(688331.SH):双抗ADC药物注射用RC288获得药物临床试验批准通知书

智通财经
Yesterday

智通财经APP讯,荣昌生物(688331.SH)发布公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,公司自主研发的双抗ADC药物RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。

RC288是一款同时靶向PSMA和B7H3的双特异性ADC,是荣昌生物采用新一代偶联及毒素技术开发的创新药物分子。PSMA全称前列腺特异性膜抗原,是一种Ⅱ型跨膜糖蛋白,其支持肿瘤生长和血管生成;B7H3是一种免疫检查点分子,当其在肿瘤中过表达时,会促进免疫逃逸和肿瘤进展。PSMA及B7H3均是极具潜力的治疗靶点,在多种恶性肿瘤组织及肿瘤新增生血管中高表达,并参与肿瘤增殖、侵袭、耐药等相关信号通路。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10